SCHEMBL112972

SCHEMBL112972

COC(=O)c1ccc(C#N)c(-c2c(C)nn(COCC[Si](C)(C)C)c2C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 2/20 0.38
DGAT1 O75907 2/20 0.36
AR P10275 1/20 0.34
CDK4 P11802 1/20 0.34
CCND1 P24385 1/20 0.34
CCND3 P30281 1/20 0.34
CDK6 Q00534 1/20 0.34
GAA P10253 2/20 0.33
RAB9A P51151 1/20 0.33
SCN9A Q15858 2/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CASP3 P42574 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
TBK1 Q9UHD2 1/20 0.32
ADORA2A P29274 1/20 0.32
MCL1 Q07820 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2143690 0.83 KLKB1 (0.37) KLKB1DGAT1GAARAB9AALDH1A1
SCHEMBL111791 0.78 CDK4 (0.48) CDK4CCND1CCND3CDK6GAA
SCHEMBL15555898 0.77 XDH (0.37) KLKB1DGAT1KMT2ACASP3EGLN1
SCHEMBL29632366 0.76 KLKB1 (0.32) KLKB1DGAT1RAB9AALDH1A1KMT2A
SCHEMBL112041 0.74 CDK4 (0.59) KLKB1CDK4CCND1CCND3CDK6
SCHEMBL111018 0.74 ADORA2A (0.34) SCN9AEGLN1TBK1ADORA2AMCL1
SCHEMBL32683286 0.73 ALDH1A1 (0.38) KLKB1DGAT1GAAALDH1A1KMT2A
SCHEMBL24953310 0.72 TTR (0.56) KLKB1DGAT1RAB9AKMT2AMCL1
SCHEMBL112333 0.69 TGFBR1 (0.46) KLKB1CDK4CCND1CCND3CDK6
SCHEMBL3077532 0.69 GAA (0.48) ARGAARAB9AALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424843-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2014-03-26 EP disclosed
US-8598217-B2 Imidazole derivatives and their use as modulators of cyclin dependent kinases ASTEX THERAPEUTICS LTD. (GB) 2013-12-03 US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 US disclosed
EP-2424843-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES Novartis AG (CH) 2012-03-07 EP disclosed
WO-2010125402-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2010-11-04 WO disclosed
WO-2010125402-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES CDK3, CCNI, CDK1 KLKB1 3523/4885DGAT1 4775/4885AR 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.